De Miguel et al. reported an LNP coated with bioactive Apo2L/TRAIL named LUV-TRAIL, which improved TRAIL cytotoxic ability in non-small cell lung cancer (NSCLC) cell lines and in primary human tumor cells from patients with NSCLC. This evidence concerns the gene TNFSF10 and non-small cell lung carcinoma.